Journal of microencapsulation最新文献

Aim: This study investigates a novel treatment for urinary tract infections (UTIs) caused by Staphylococcus aureus, Escherichia coli, and Klebsiella pathogenic bacterial strains.

Methods: The Cur/Chx/Au composite matrix was synthesised in one pot by solution reduction and examined for functional groups and surface morphology by FT-IR, UV-DRS, HR-TEM, and TGA. In vitro, microbial growth inhibition evaluation and pathogen biofilm studies assessed the composite's antibacterial capacity.

Results: Cur/Chx/Au exhibit mean diameter from 30 ± 5.2 nm, PDI 0.50 ± 0.05, and a zeta potential of -9.56 ± 1.84. The inhibition zones for S. aureus and E. coli were 16 ± 1.2 mm and 14 ± 0.8 mm, respectively, with an anti-inflammatory inhibition rate of 89.96%. The composite material's biocompatibility was further tested utilising in-vitro MTT, cell proliferation, and wound scratch assays in NHI 3T3 cells.

Conclusion: Our findings demonstrate that the combination of Cur/Chx/Au composite matrix is a promising formulation for UTI treatment.

This study evaluated albendazole (ABZ) nanostructured lipid carriers (NLCs) for hepatocellular carcinoma treatment. ABZ-NLCs were prepared using emulsification-ultrasonication and optimised using a Box-Behnken design. Independent variables-lipids concentration (X₁), surfactant concentration (X₂), and sonication duration (X₃)-were assessed for their effect on mean diameter (Y₁), PDI (Y₂), and entrapment efficiency (Y₃). The optimised formulation exhibited a mean diameter of 166.13 ± 3.72 nm, a PDI of 0.17 ± 0.01, a zeta potential of -39.86 ± 1.84 mV, an entrapment efficiency of 94.25 ± 6.12%, and a loading capacity of 99.93 ± 7.15 mg/g. Following chitosan coating (ABZ-CS-NLCs), all parameters were maintained, and the zeta potential developed to +24.61 ± 1.32 mV, improving cellular interaction. The cytotoxicity assays revealed that ABZ-CS-NLCs were more effective than uncoated NLCs and free ABZ, with an IC50 value of 8.89 μM in HepG2 cells. Overall, ABZ-CS-NLCs demonstrate a promising and effective delivery platform for targeted hepatic cancer therapy.

This study aims to develop and evaluate flurbiprofen-loaded polymeric nanoparticles to achieve sustained drug release, enhancing therapeutic efficacy and minimising dosing frequency for improved patient outcomes. Flurbiprofen-loaded polymeric nanoparticles were prepared using a tubular microreactor and spray drying, optimised via Box-Behnken Design. Characterisation included particle size, encapsulation efficiency, in vitro and in vivo drug release, and techniques like FTIR, DSC, XRD, and SEM. Statistical analysis ensured robust formulation optimisation and evaluation of performance. The optimised batch of flurbiprofen-loaded polymeric nanoparticles was characterised for mean diameter, PDI, zeta potential, drug release, and EE% were found to be 306.1 ± 6.00 nm, 0.184 ± 0.02 Mw, -23.6 ± 1.51 mV, 85.46 ± 0.53% and 92.31 ± 0.84 (% w/w) respectively. Pharmacokinetic analysis further confirmed the sustained release, extending up to 12 hours and enhancing permeation compared to the pure flurbiprofen. Sustained release of flurbiprofen-loaded polymeric nanoparticles significantly enhances therapeutic effectiveness for inflammatory conditions.

Carotenoids are compounds sensitive to environmental factors such as light, heat, and oxygen, which can result in the loss of their properties due to isomerisation and oxidation. To overcome this problem, spray drying encapsulation has been widely used as a method to protect and stabilise carotenoids in different wall materials. This article summarises the findings and research on spray drying encapsulation of carotenoids over the past 15 years, with an emphasis on the importance of controlling the operational conditions of the drying process and the association of different wall materials (proteins and polysaccharides), promising to increase encapsulation efficiency and stabilise carotenoids, with perspectives and trends in applications. The use of spray drying for carotenoid microencapsulation can open up new opportunities for controlled delivery of beneficial compounds. Based on the study, it is expected to provide information for researchers, professionals, and companies interested in the development of functional food products.

Present study reports analgesic and anti-inflammatory potential of Piper betel (L.) leaf oil loaded lipid nanocarrier (BLNs)-embedded bigel. BLNs were developed by solvent evaporation technique and were characterised by FESEM, Cryo-TEM, mean diameter, zeta potential, loading efficiency, etc. BLNs embedded bigel (BLNs-G) was evaluated for analgesic and anti-inflammatory efficacy in rat model. Data showed spherical BLNs with intact lamellarity, 138.2 ± 1.08 nm mean diameter, 0.182 PDI, -46.6 ± 0.61 mV zeta potential, 76.2 ± 2.1% (w/w) loading efficiency and a sustained release in vitro. BLNs-G was homogenous with satisfied viscosity (40 734 ± 1.7 cps), spreadability (8.3 ± 1.5 g.cm sec^-1), extrudability (91.33 ± 1.3% w/w) along with a sustained permeation ex vivo. Significant analgesic and anti-inflammatory action were depicted by BLNs-G (1% w/w) in rat model (p ˂ 0.05) within 30 minutes post topical application. In silico docking study revealed high affinity of major phytoactive components with key analgesic/inflammatory mediators. Further pre-clinical investigations are warranted for futuristic clinical application of BLNs-G.

Phytochemicals as dietary components are being extensively explored in order to prevent and treat a wide range of diseases. Apigenin is among the most studied flavonoids found in significant amount in fruits (oranges), vegetables (celery, parsley, onions), plant-based beverages (beer, tea, wine) and herbs (thyme, chamomile, basil, oregano) that has recently gained interest due to its promising pharmacological effects. However, the poor solubility and extended first pass metabolism of apigenin limits its clinical use. Various advantages have been demonstrated by nanocarrier-based platforms in the delivery of hydrophobic drugs like apigenin to diseased tissues. Apigenin nanoformulations have been reported to have better stability, high encapsulation efficiency, prolonged circulation time, sustained release, enhanced accumulation at targeted sites and better therapeutic efficacy. An overview of the major nanocarriers based delivery including liposomes, niosomes, solid lipid nanoparticles, micelles, dendrimers etc., is described. This review sheds insight into the therapeutic effects and advanced drug delivery strategies for the delivery of apigenin.

Aims: This study aimed to improve rivaroxaban delivery by optimising solid lipid nanoparticles (SLN) for minimal mean diameter and maximal entrapment efficiency (EE), enhancing solubility, bioavailability, and the ability to cross the blood-brain barrier.

Methods: A central composite design was employed to synthesise 32 SLN formulations. Response surface methodology (RSM) and artificial neural networks (ANN) models predicted mean diameter and EE based on five independent variables.

Results: The optimised SLN formulation achieved a mean particle diameter of 159.8 ± 15.2 nm, with a Polydispersity index of 0.46, a zeta potential of -28.8 mV, and an EE of 74.3% ± 5.6%. The ANN model showed superior accuracy for both mean diameter and EE, outperforming the RSM model. Structural integrity and stability were confirmed by scanning electron microscopy (SEM), differential scanning calorimetry (DSC), and Fourier-transform infrared spectroscopy (FTIR).

Conclusion: The high accuracy of the ANN model highlights its potential in optimising pharmaceutical formulations and improving SLN-based drug delivery systems.

The aim of research is to enhance the solubility of crystalline gefitinib (GF), a poorly water-soluble drug, by developing drug delivery systems using chitosan oligosaccharide (COS) particle engineering. Fabrication utilizes ionic gelation followed by spray drying. The preliminary evaluations such as Uv-Vis, FTIR, DSC followed by advanced techniques like SEM and invitro drug release characteristics was performed along with solubility study. The spray-dried particles measured a mean diameter of 3.18 ± 0.5 microns, %EE as well as load w/w improved from 63.25 ± 2.1% and 37.98 ± 1.5% w/w (COS nanoparticles) to 78.15 ± 2.6% and 45.34 ± 1.6% w/w (engineered microparticles), respectively. The zeta potential and in vitro studies demonstrated 41 ± 3.5 mV and 92 ± 2.1% (w/w) release suggest long-term stability and prolonged release. This novel engineering approach effectively enhances GF solubility and surface characteristics, offering promising potential for improving delivery characteristics.

This study aimed to develop silver nanoparticles embedded in poly(ricinoleic acid)-poly(methyl methacrylate)-poly(ethylene glycol) (AgNPsPRici-PMMA-PEG) nanoparticles (NPs) containing caffeic acid (Caff) and tetracycline hydrochloride (TCH) for treating infections and cancer in bone defects. The block copolymers were synthesised via free radical polymerisation. NPs were prepared using the solvent evaporation method and characterised by FTIR, HNMR, SEM, DSC, TGA, and DLS. Drug loading (LE), encapsulation efficiency (EE), antimicrobial activity, cytotoxicity, and in vitro release studies were conducted. The NPs exhibited a size of 198 ± 2.89 nm, a narrow size distribution (PDI < 0.1), and a zeta potential of -27.5 ± 0.13 mV. The EE of Caff were 73 ± 0.09% w/w and 78 ± 0.32% w/w. Caff NPs showed prolonged release (69 ± 0.23% w/w), cytotoxicity with the cell viability of 66.85 ± 10.51% in SaOS cells, and antimicrobial zones ranging from 1.5 ± 0.3 to 4.2 ± 0.2 mm. TCH-Caff-AgNPsPRici-PMMA-PEG NPs exhibited promising therapeutic potential for infection and cancer treatment in bone defects.

The aim of study was to prepared and evaluated rutin-loaded solid-lipid-nanoparticles (Ru-SLNs) gel for treatment of melanoma cells. SLNs were prepared by ultrasonication method through optimisation and evaluated their mean-diameter, PDI, zeta-potential, morphology, entrapment-efficiency, drug-loading, interaction by FTIR, in vitro skin permeation, stability, antioxidant/MTT assay and fluorescence microscopic. Further developed Ru-SLNs was incorporated into gel and characterised their physicochemical properties, drug contents, in vitro diffusion, ex vivo permeation and retention studies in human cadaver skin. Optimised Ru-SLNs batch showed 556.4 ± 2.6 nm mean-diameter, -21.9 mV zeta-potential, 94.8 ± 04% entrapment-efficiency, 62.3 ± 29% loading, and 86.63% release after 6 hrs. MTT assay showed, Ru-SLNs have 15.37 times more effectiveness against melanoma cells, while fluorescence microscopy confirmed the cellular uptake over time. Gel based Ru-SLNs, have reduction in flux across skin, indicating a sustained release of rutin and higher retention within the deeper epidermis layer. Finally, Ru-SLNs based gel exhibited promising potential and effectively targeting to skin's epidermal layer for melanoma cells.